Home Citius Pharmaceuticals Citius Articles Citius Pharma up 7% on in-license of anti-infective gel wrap

Citius Pharma up 7% on in-license of anti-infective gel wrap

7
0
|About: Citius Pharmaceuticals… (CTXR)|By: , SA News Editor (Source:SeekingAlpha.com)

Thinly traded nano cap Citius Pharmaceuticals (CTXR +7.1%) is up on a healthy 47x surge in volume in reaction to its license agreement with MD Anderson Cancer Center to develop and commercialize a product called “Mino-Wrap,” a gel-based wrap containing minocycline and rifampin designed to reduce post-operative infections associated with surgical implants.

Specifically, the product is aimed at reducing tissue expander (TE) infections following breast reconstructive surgery. A TE is a silicon implant that is placed in the mastectomy space and inflated with saline over a period of time to prepare the area for a permanent breast implant. The rate of TE-related infections is between 2.5 – 24%, depending on a range of factors such as the extent of the surgery and duration of postoperative drainage.

Mino-Wrap (CITI 101) is currently being evaluated in a Phase 3 study.

Minocycline is a tetracycline antibiotic used to treat severe acne. Rifampin is also an antibiotic, typically used to treat bacterial infections.

LEAVE A REPLY

Please enter your comment!
Please enter your name here